期刊論文| 1. | Meyer, J. M.、McEvoy, V. G.、Davis, J. P. et al.(2008)。A Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial. prospective data from phase 1。Schizophr Res，101，273-286。   |
| 2. | Leucht. S.、Wagenpfeil, S.、Hamann, J.、Kissling, W.(2004)。Amisulpride is an "atypical" antipsychotic associated with low weight gain。Psychopharmacology (Berl，173，112-115。 |
| 3. | Rettenbacher, M. A.、Ebenbichler, C.、Hofer, A. et al.(2006)。Early changes of plasma lipids during treatment with atypical antipsychotics。Int Clin Psychopharmacol，21，369-372。 |
| 4. | Chhim, T.、Neumiller, J. J.(2012)。Antipsychotic-induced diabetes mellitus。US Pharmacist，37，39-44。 |
| 5. | North American Association for the Study of Obesity、American Diabetes Association、American Association of Clinical Endocrinologists、American Psychiatric Association(2004)。Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes。The Journal of Clinical Psychiatry，65(2)，267-272。 |
| 6. | Lin. C. C.、Bai. Y. M.、Wang. Y. C. et al.(2009)。Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics。J Clin Psychopharmacol，29，529-536。 |
| 7. | McEvoy, J. P.、Meyer, J. M.、Goff, D. C.(2005)。Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III。Schizophr Res，80，19-32。 |